بإذنك، نستخدم تحليلات محدودة تراعي الخصوصية لفهم مسارات البحث الفعالة. لا نستخدم أدوات تتبع إعلانية أو تسجيل الجلسات. يمكنك تغيير هذا الخيار في التفضيلات. اقرأ سياسة الخصوصية.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
UNH — frequently asked questions
Is UnitedHealth Group Incorporated overvalued?
In our latest published analysis dated 2026-09-21, UNH looks meaningfully undervalued. The price recorded at analysis is 377 USD versus our fair value of 448 USD; the high endpoint is presented separately as potential value of 578 USD. That implies roughly 18.9% upside to fair value at that date.
Our latest published report, analyzed 2026-09-21, gives UNH a fair value of 448 USD and a potential value of 578 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for UnitedHealth Group Incorporated's archetype; it is a dated research output, not a live price.
Should I buy UNH now?
Our latest published rating for UNH, analyzed 2026-09-21, is Buy. UnitedHealth Group Incorporated looks meaningfully undervalued at the analysis-date price of 377 USD versus fair value of 448 USD; potential value is 578 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for UNH?
The dedicated bear-case section in our report analyzed 2026-09-21 documents UnitedHealth Group Incorporated's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is UNH's rating?
Our latest published rating for UNH, analyzed 2026-09-21, is Buy, with a published moat assessment of 7/10 (Narrow). It reflects our fair value of 448 USD, the potential value of 578 USD, and the price recorded at analysis (377 USD).
لم تتم ترجمة هذا التقرير بعد. قم بالتحديث خلال بضع دقائق بمجرد أن تلحق قائمة انتظار الترجمة بالركب.
§1 الملخص التنفيذيEN
الإجابة في 30 ثانيةBuy
السعر مقابل القيمة
Price
$376.90
Fair value
$448.25
Potential value
$578.10
As of
2026-09-18
لماذا قد تنجح الفرضية
Accelerating clinical margin recovery in OptumHealth combined with commercial health benefit premium repricing that absorbs medical cost inflation, driving operating margins from 4.24% in FY2025 toward historical levels of 6.50% and expanding fair value toward Potential value of USD 578.10.
We rate UnitedHealth Group a Buy. The company's massive scale in health benefits and integrated pharmacy services positions it for steady cash generation and earnings recovery, offering attractive upside from the report-date price to our Fair value.
Our rating is Buy. For an investor, this means UnitedHealth Group offers an attractive balance of steady compounding and share price appreciation, supported by leading positions in health benefits and healthcare services.
The report was prepared at a price of USD 376.90 on September 18, 2026. This price trades at a 15.92% discount to our Fair value of USD 448.25. If clinical care margins recover faster than expected, the shares could reach Potential value of USD 578.10.4
The main risk that would change our view is regulatory rate pressure from Medicare and Medicaid, which account for 44.0% of consolidated revenue. If federal payment benchmarks are cut or risk-adjustment coding audits tighten, premium yields per member would decline while medical utilization remains elevated. A reader would see this happen through consolidated operating margins dropping below 3.50% and annual free cash flow falling below $12,000M.
The primary reason the investment can work is UnitedHealth's vertically integrated scale across health benefits and pharmacy care. UnitedHealthcare delivered $344.9B in revenue and OptumRx produced $7.19B in operating profit. By combining health insurance with prescription management, the business manages care costs more effectively than pure-play peers. As medical care ratios stabilize and clinic profitability recovers from recent deficits, operating profit and free cash flow will expand, driving per-share value toward our Fair value of USD 448.25.7
Unmatched Scale in Benefits and Pharmacy Care
UnitedHealthcare's $344.9B revenue base and OptumRx's $7.19B operating profit create unmatched contracting scale and lower unit operating costs than managed care peers.7
Strong operating cash flow of $19.7B and free cash flow of $16.1B fund dependable dividends and share repurchases, driving compounding per-share value as operating margins normalize toward historical levels.5,6
Scale and Cost Advantage in Benefits and Care Delivery
UnitedHealthcare generated $344,903M in FY2025 revenue and $9,425M in operating earnings, providing unprecedented purchasing scale and lower administrative unit costs than regional managed care peers.7
توصية الدار
We recommend a Buy because UnitedHealth Group's integrated scale across health benefits and pharmacy services provides durable cash flow to drive share price recovery to our Fair value.
نظرة عامة على الشركة
It also offers direct-to-consumer solutions. On January 1, 2026, the company realigned certain of its businesses to respond to changes in the markets the company serves and the opportunities that are emerging as the health system evolves.
Optum Financial, including Optum Bank, which was historically included in Optum Health, will now be included in Optum Insight.
§2 السيناريو الهبوطيEN
Under persistent CMS statutory reimbursement cuts on the 44.0% government revenue share combined with elevated medical utilization, operating income falls below FY2025 levels of $18,964M. Free cash flow contracts from $16,075M as debt service on $73,328M total debt limits capital return flexibility.
Medical utilization remains elevated, holding consolidated operating margins depressed
OptumHealth capitation contract deficits widen further
The Bear path envisions persistent CMS Medicare Advantage statutory rate cuts, aggressive risk adjustment coding audits, and elevated medical utilization compressing consolidated operating margins. This scenario would be confirmed if medical care ratios remain elevated and clinic operating losses deepen, leading to reduced earnings power.
كيف يمكن أن تفشل هذه الأطروحة
Severe Medicare Advantage Rate Cuts and Medical Loss Ratio Spike Compress Consolidated Operating Margin Below 3.5%
CMS accounts for 44.0% of consolidated revenue and consolidated operating profit dropped from $32,358M in FY2023 to $18,964M in FY2025 (a 4.24% margin). A further 100-150 bps contraction pushes operating margin below 3.5%.6,7
FV impact
0%
Operating margin 3 points lower throughout
Trigger
إشارات الإنذار المبكر للمراقبة
التطورات الخمسة التي قد تضعف أطروحتنا الاستثمارية.
01
consolidated_operating_margin
Medical loss ratio spikes and CMS rate reset pressures reducing operating profit below $16.0B across $447.6B revenue.
الحالي:4.24% in FY2025
تنبيه إذاbelow 3.50%
02
operating_optumhealth_operating_income_millions
§3 الميزة التنافسيةEN
Narrow
UnitedHealth Group possesses a narrow economic moat grounded in the structural cost and scale advantages of its dual-platform model spanning UnitedHealthcare and Optum. The combination of health insurance coverage with integrated pharmacy care services and clinical care delivery creates substantial customer switching costs.
High regulatory exposure to government programs where CMS represents 44.0% of revenue caps potential economic rent extraction, bounding the moat rating at narrow despite superior returns over capital costs.
01Scale and Cost Advantage in Benefits and Care Delivery — UnitedHealthcare generated $344,903M in FY2025 revenue and $9,425M in operating earnings, providing unprecedented purchasing scale and lower administrative unit costs than regional managed care peers.Wide
02High Switching Costs via Integrated PBM and Clinical Services — OptumRx delivered $154,726M in revenue and $7,193M in operating income, while OptumInsight generated $19,417M in revenue, embedding software, data analytics, and pharmacy benefit workflows deep within employer and health system operations.
التهديدات المعروفة للميزة التنافسية
التهديد
الخطورة
الجدول الزمني
التخفيف
CMS Regulatory Reset and Risk-Adjustment Audit Tightening
high
12-24 months
Broad commercial employer diversification generating over $250B in non-CMS revenues alongside value-based care clinical risk sharing through Optum.
Clinical Care Delivery Cost Escalation at OptumHealth
الصفوف: معدل الخصم (Ke للأرباح؛ WACC للتدفقات النقدية). الأعمدة: النمو النهائي.
القيمة العادلة
تغير المدة (سنوات)
-5
-2
0
+2
+5
القيمة العادلة
447.23 US$
447.75 US$
448.25 US$
448.73 US$
449.39 US$
مدة الميزة التنافسية: 5 سنوات في الحالة الأساسية المميزة. تبقى الافتراضات الأخرى ثابتة.
مرجع الحساسية
The highlighted cell is Fair value when every assumption sits at its base level ($448.25). Each row and column shows what Fair value becomes when one assumption moves.
منحدر التدفق النقدي الحر
Free cash flow to the firm stays positive in the first projected year at $16.0B after modeled reinvestment of $0, with terminal value at 63.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base path represents the modal expectation where UnitedHealthcare maintains its market share and core profitability, while OptumHealth gradually narrows operating losses. Under this progression, operating margins trend toward normalized levels, supporting fair value expansion toward $448.25.
In FY2025, UNH allocated capital across $7,916M in common dividends and $5,545M in share repurchases, reducing diluted share count from 938M in FY2023 to 911M in FY2025. Total debt of $73,328M is supported by steady cash generation.
ROIC stood at 9.66% in FY2025, while operating margin rebounded in the first half of 2026, where Q2-2026 YTD operating profit reached $16,981M (a 7.59% operating margin), recovering from the 4.24% operating margin recorded in FY2025.
ROIC of 9.66% comfortably exceeds the computed WACC of 7.43%, creating positive economic profit across the business.
UnitedHealthcare generated $344,903M of UNH's $447,567M consolidated revenue in FY2025.
Scale provides steady operational cash flow even during periods of elevated medical care ratios.
أحدث إيرادات447.6 مليار US$معدل النمو السنوي المركب للإيرادات +10.3%
هامش التشغيل4.2%10 فترات مالية
أحدث تدفق نقدي حر16.1 مليار US$FY2025
صافي الدين50.3 مليار US$FY2025
تفصيل قائمة الدخلكيف يتحول حجم الأعمال إلى أرباح مُعلنة.
StockMarketAgent.AI
الإيرادات447.6 مليار US$تكلفة الإيرادات−364.7 مليار US$إجمالي الربح82.9 مليار US$المصروفات التشغيلية−64 مليار US$الدخل التشغيلي19 مليار US$البنود غير التشغيلية والضرائب−6.9 مليار US$صافي الدخل12.1 مليار US$
بيانات التاريخ المالي
الإيرادات
447,567,000,000 US$
تكلفة الإيرادات
364,650,000,000 US$
إجمالي الربح
82,917,000,000 US$
المصروفات التشغيلية
63,953,000,000 US$
الدخل التشغيلي
18,964,000,000 US$
البنود غير التشغيلية والضرائب
-6,908,000,000 US$
صافي الدخل
12,056,000,000 US$
لمحة عن الميزانية العموميةكيفية الاحتفاظ بالأصول المُبلغ عنها وتمويلها في الفترة المحددة.
StockMarketAgent.AI
تكوين الأصولمصادر التمويل
إجمالي الأصول309.6 مليار US$النقد24.4 مليار US$الأصول المتداولة90.6 مليار US$إجمالي الالتزامات207.9 مليار US$الالتزامات المتداولة114.9 مليار US$حقوق المساهمين100.1 مليار US$
بيانات تفصيل الميزانية العمومية
إجمالي الأصول
309,581,000,000 US$
النقد
24,365,000,000 US$
الأصول المتداولة
90,582,000,000 US$
إجمالي الالتزامات
207,883,000,000 US$
الالتزامات المتداولة
114,897,000,000 US$
حقوق المساهمين
100,090,000,000 US$
جسر التدفق النقديكيف تحول التدفق النقدي التشغيلي إلى تدفق نقدي حر في FY2025.
StockMarketAgent.AI
تسوية التدفق النقدي التشغيلي
صافي الدخل12.1 مليار US$الإهلاك والإطفاء+4.4 مليار US$التعويض القائم على الأسهم+971 مليون US$تعديلات تشغيلية أخرى+2.3 مليار US$التدفق النقدي التشغيلي19.7 مليار US$
تسوية النقد من بداية الفترة إلى نهايتها
النقد في بداية الفترة25.3 مليار US$التدفق النقدي التشغيلي+19.7 مليار US$التدفق النقدي الاستثماري−8.7 مليار US$التدفق النقدي التمويلي−11.6 مليار US$تأثير سعر الصرف+40 مليون US$النقد في نهاية الفترة24.4 مليار US$
19.7 مليار US$ − 3.6 مليار US$التدفق النقدي الحر 16.1 مليار US$
بيانات جسر التدفق النقدي
صافي الدخل
12,056,000,000 US$
التدفق النقدي التشغيلي الداخل
19,697,000,000 US$
الإهلاك والإطفاء
4,361,000,000 US$
التعويض القائم على الأسهم
971,000,000 US$
تعديلات تشغيلية أخرى
2,309,000,000 US$
التدفق النقدي التشغيلي
19,697,000,000 US$
النقد المتاح
45,049,000,000 US$
النقد في بداية الفترة
25,312,000,000 US$
تأثير سعر الصرف
40,000,000 US$
التدفق الاستثماري الخارج
8,685,000,000 US$
النفقات الرأسمالية
3,622,000,000 US$
أنشطة استثمارية أخرى
5,063,000,000 US$
التدفق التمويلي الخارج
11,644,000,000 US$
النقد في نهاية الفترة
24,365,000,000 US$
التدفق النقدي الاستثماري
-8,685,000,000 US$
التدفق النقدي التمويلي
-11,644,000,000 US$
الإيرادات والأرباحكيف يتحول حجم الأعمال إلى أرباح مُعلنة.
النقد والدينالسيولة المتاحة مقارنة بإجمالي الاقتراض.
توليد النقدالتدفق النقدي التشغيلي مقارنة بالتدفق النقدي الحر.
UnitedHealth Group Incorporated (UNH) trades at 16.7x forward earnings against a peer median of 12.2x. Its EV/EBITDA of 14.5x compares with a peer median of 10.3x. The comparison uses 4 peers: CVS Health Corporation, Elevance Health Inc., The Cigna Group and Amgen Inc., as of 2026-09-20.
§10 الصناعة والدورةEN
مرحلة الدورة
Contraction
Industry capex-to-revenue benchmark stands at 0.90% and capex-to-depreciation at 0.81, matching UNH's capital spending of $3,622M against $4,361M depreciation in FY2025.
دورة صعودية
Favorable demographics driving Medicare Advantage enrollment growth, expanding value-based care adoption, and commercial pricing updates compensating for medical cost trends.
دورة هبوطية
Tightening CMS statutory reimbursement rates, V28 risk adjustment model coding phase-ins, elevated outpatient utilization, and heightened antitrust scrutiny on PBM practices.
الاتجاهات طويلة الأمد
الاتجاه
التأثير
ملاحظة
Aging US Population and Medicare Advantage Expansion
positive
Long-term demographic growth expands the addressable market for senior care delivery and health benefit plans.
Stricter CMS Risk Adjustment and Reimbursement Scrutiny
negative
Federal rate benchmarks and risk coding adjustments reduce baseline payment growth per Medicare Advantage enrollee.
Payer-Provider Vertical Integration
positive
Coordinating care delivery, pharmacy services, and benefit management lowers total medical costs relative to fragmented peers.
التموضع
As the largest managed care organization in the United States, UNH is positioned to capture value-based care volumes while absorbing regulatory margin friction better than smaller peers.
§11 إدارة المراكزEN
حجم المركز
4-6%
Reflects the company's defensive mature compounder profile, strong cash generation, and attractive discount to Fair value of $448.25 relative to the report-date price of $376.90, balanced against CMS regulatory concentration risks.4
المخاطر
Maintain strict position size discipline capped at 6% of equity portfolio. Rebalance exposure if Medicare Advantage regulatory rate decisions or unexpected medical loss ratio spikes impair forward cash flow generation.
شرائح الدخول
المستوى
إجراء
لماذا
Below $380.00
Initiate primary tranche (50% of target allocation)
Trades at an attractive discount to Fair value ($448.25) with forward P/E of 16.72x.
Pause new capital additions and conduct a full re-underwrite of long-term margin recovery assumptions.
optumhealth_operating_income
Operating loss at or below -$500M
Demote valuation model multiples and reduce target position sizing by 25%.
§12 وجهات نظر المستثمرينEN
Value Investor
Buy
Trading at 16.72x forward earnings and a 15.92% discount to our Fair value of USD 448.25, UNH offers an attractive entry into a premier healthcare compounder with strong 1.63x cash conversion.4,6
Growth Investor
Buy
While near-term revenue growth is modest, Optum's clinical expansion and integrated pharmacy services underpin consensus EPS expectations of $22.61 in FY2027, supporting a near-term earnings rebound and long-term recovery as margins normalize.2
Income & Quality Investor
Buy
Disciplined capital allocation returning $7.9B in dividends and $5.5B in repurchases in FY2025, combined with robust free cash flow of $16.1B, offers dependable income and consistent per-share compounding.5
§14 التوصية النهائيةEN
إجراء
شراء
We recommend a Buy rating on UnitedHealth Group. At the report-date price of USD 376.90, shares trade at a 15.92% discount to our Fair value of USD 448.25, presenting an attractive risk-reward profile for long-term investors.4
The company's core scale across UnitedHealthcare ($344.9B revenue) and OptumRx ($7.19B operating profit) provides defensive cash flow and pricing power. Robust free cash flow of $16.1B supports steady dividend growth and share repurchases.
§15ملاحظاتك
دوّن أطروحتك الاستثمارية وحجم مركزك وأسئلة المتابعة. تبقى على هذا الجهاز، ولا يراها أحد سواك.
ملاحظات خاصة
مرئية لك وحدك. محفوظة على هذا الجهاز.
لا أحرف
Sources
The records this analysis drew on, as they stood when it was run.
Macro and cost of capitalData as of 2026-09-21 · Published 2026-09-21 · cited for 1 figureCited in الميزة التنافسية, التاريخ المالي
Analyst consensusData as of 2026-09-20 · Published 2026-09-20 · Provider-adjusted · cited for 1 figureCited in وجهات نظر المستثمرين
Market and peer researchData as of 2026-09-20 · Published 2026-09-20 · Provider-adjusted · cited for 3 figuresCited in السيناريو الهبوطي
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
OptumHealth generated an operating loss of -$278M in FY2025 on $101,957M revenue. If capitation deficits escalate past -$1,000M, the house forecast margin recovery fails completely.7
FV impact
-1.5%
The analyst's bear scenario path and multiple as the base case
UNH trades at 16.72x forward P/E with an 18.0x modeled terminal P/E, while peers trade at CVS 10.42x, ELV 13.91x, and CI 8.23x. A 20% multiple compression to 14.4x aligns UNH with peer levels.3,4
FV impact
-1.9%
Terminal multiple 20% lower
Trigger
Within 24 months
Widening capitation deficits in care delivery clinics failing to absorb provider wage and clinical inflation on $102.0B revenue.
الحالي:-$278M in FY2025
تنبيه إذاat or below -$500M
03
unitedhealthcare_operating_margin
Commercial and Medicare Advantage underwriting margins compressing under elevated medical care ratios, impairing core cash flow.
Limitation: Terminal value is 65% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
The Bull path requires OptumHealth care delivery margins to recover rapidly, commercial employer enrollment to gain market share, and effective contract repricing to outpace medical inflation. The reader would see confirmation through consecutive quarters of expanding operating margins in care delivery and accelerating earnings per share growth toward $578.10.
03
المقياس:
OptumHealth Clinical Care Profitability
الحاليOperating at a deficit in the baseline fiscal year under capitation contract pressures.
لماذا يهم
Return to positive operating profit is required to reach the long-term consolidated margin target.
04
المقياس:
OptumRx Pharmacy Services Margin Stability
الحاليConsistently profitable and generating reliable operational cash flow.
لماذا يهم
Sustains steady fee income and purchasing scale to buffer clinical underwriting volatility.
